Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis
Metrics: PDF 1535 views | HTML 1501 views | ?
Zhi-gang Liu1,*, Yu Zhao1,*, Jiao Tang1,*, Yu-juan Zhou1, Wen-juan Yang1, Yan-fang Qiu1, Hui Wang1
1Key Laboratory of Translational Radiation Oncology, Department of Radiation Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
*These authors have contributed equally to this work
Hui Wang, e-mail: firstname.lastname@example.org
Zhi-gang Liu, e-mail: email@example.com
Keywords: NPC, nimotuzumab, chemoradiotherapy, EGFR
Received: October 22, 2015 Accepted: March 02, 2016 Published: March 21, 2016
Nimotuzumab is a blocking monoclonal antibody against epidermal growth factor receptor (EGFR). However, little is known about the safety and preliminary efficacy of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced NPC patients. A total of 42 patients diagnosed between 2011 and 2013 were enrolled. Our results demonstrated 38 patients had a complete response (90.5%), 4 patients had a partial response (9.5%). And no patients had progressive disease at early treatment response evaluation, giving an ORR of 100%. The 2-year local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and overall survival (OS) were 96.4%, 93.1% and 96.6% respectively. The most common adverse events were mucositis (19 patients), hematology toxicity (14 patients) with 6 and 3 cases of grade 3/4 toxicity respectively. Skin rash was not developed in our 43 patients. Thus, nimotuzumab combined with concurrent chemoradiotherapy showed encouraging outcomes in the treatment of locally advanced nasopharyngeal carcinoma, without accumulation of toxicity and well-tolerated.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.